Primary total hip arthroplasty with a proximally HA-coated titanium femoral component: results at 10-15-year follow-up.
Registries in both the United Kingdom and Sweden suggest that the popularity of uncemented femoral components is increasing. As this trend progresses, long-term survival data for such components are becoming increasingly more important. We present the results of a cohort of patients treated with the Omnifit (Stryker, Mahwah, NJ) femoral component with the follow-up of 10-15 years. A prospective study was performed in our unit between 1996 and 2001. Patients were reviewed pre-operatively and then at 6, 12, 26 and 52 weeks post-operatively and annually thereafter. They were assessed clinically and radiographically, and the Merle d'Aubigne Postel (MDP) hip score was calculated at each visit. A visual analogue scale (VAS) score and satisfaction score were also recorded to assess patient satisfaction with their procedure. Specific enquiry was made regarding anterior thigh pain. Statistical calculations were performed using the Student's t test. Kaplan-Meier survival analysis was performed. One hundred and four patients (113 hips) were included (48 males, 56 females). Bilateral procedures were performed in nine patients. Mean age was 60.4 years (33-72 years). Mean follow-up was 12.9 years (10-15 years). Mean pre-operative MDP score was 8.8 (3-16) and VAS score 7.8 (1-10) with ten representing the most severe symptoms. At final follow-up, the average MDP and VAS scores were 16.9 (13-18) and 2.1 (0-6), respectively. High levels of satisfaction were reported by 96.1% of patients. Two dislocations and two cases of anterior thigh pain occurred. Four patients required revision surgery. Survival of the femoral component with revision for any reason as the end point was 96%. This prosthesis provides symptom relief, return to function and high levels of patient satisfaction in the long term. Survival of this component is comparable to the best results for primary total hip arthroplasty with any means of fixation.